February 20, 2019
Torque, Merck to test Keytruda with Deep IL-15 Primed T cells
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.